Home → HEALTHCARE → Glenmark Pharmaceuticals receives ANDA tentative approval for Regadenoson Injection, 0.4 mg/5 mL (0.08 mg/mL) Single-Dose Pre-Filled Syringe
HEALTHCARE
◉ January 17, 2022 • 1 min read
Glenmark Pharmaceuticals receives ANDA tentative approval for Regadenoson Injection, 0.4 mg/5 mL (0.08 mg/mL) Single-Dose Pre-Filled Syringe
Glenmark Pharmaceuticals Inc., USA (Glenmark) has received tentative approval by the United States Food & Drug Administration (U.S. FDA) for Regadenoson Injection, 0.4 mg/5…
By Instaa PRSenior Correspondent, Startup Reporter
According to IQVIATM sales data for the 12 month period ending November 2021, the Lexiscan® Injection, 0.4 mg/5 mL (0.08 mg/mL) market2 achieved annual sales of approximately $659.9 million.* Glenmark's current portfolio consists of 172 products authorized for distribution in the U.S.
marketplace and 47 ANDA's pending approval with the U.S.
FDA.
Glenmark Pharmaceuticals Inc., USA (Glenmark) has received tentative approval by the United States Food & Drug Administration (U.S. FDA) for Regadenoson Injection, 0.4 mg/5 mL (0.08 mg/mL) Single-Dose Pre-Filled Syringe, the generic version of Lexiscan®1 Injection, 0.4 mg/5 mL (0.08 mg/mL), of Astellas US, Inc.
According to IQVIATM sales data for the 12 month period ending November 2021, the Lexiscan® Injection, 0.4 mg/5 mL (0.08 mg/mL) market2 achieved annual sales of approximately $659.9 million.*
Glenmark’s current portfolio consists of 172 products authorized for distribution in the U.S. marketplace and 47 ANDA’s pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
References:
1All brand names and trademarks are the property of their respective owners.
2Market includes brand and all available therapeutic equivalents
*IQVIATM National Sales Perspectives: Retail & Non-Retail, November 2021
FDA) for Regadenoson Injection, 0.4 mg/5 mL (0.08 mg/mL) Single-Dose Pre-Filled Syringe, the generic version of Lexiscan®1 Injection, 0.4 mg/5 mL (0.08 mg/mL), of Astellas US, Inc.
KEY NUMBERS
659.9 millionExtracted from story
rs.AI
—Story signal
—Story signal
WHO IS AFFECTED
â—¯ Founders
Capital, customers and competition can change scaling decisions.
â—¯ Investors
Track capital deployment, valuations and sector signals.
â—¯ Customers
New products, pricing and services may follow.
â—¯ Ecosystem
Jobs, partnerships and market opportunities can expand.
OPPORTUNITY RADAR
Business OpportunityCreator OpportunityInvestor SignalMarket Opportunity
Potential opportunities include partnerships, hiring, expansion, customer acquisition and new capital deployment.
According to IQVIATM sales data for the 12 month period ending November 2021, the Lexiscan® Injection, 0.4 mg/5 mL (0.08 mg/mL) market2 achieved annual sales of approximately $659.9 million.* Glenmark's current portfolio consists of 172 products authorized for distribution in the U.S.
marketplace and 47 ANDA's pending approval with the U.S.
Join the conversation